Belimumab for antiphospholipid syndrome (APS)
Part of Immune system & allergy clinical trials.
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have APS with high levels of antiphospholipid antibodies.
- You have been on a stable APS treatment plan as recommended by your doctor.
- If you are a woman who could become pregnant, you are not pregnant, not breastfeeding, and use birth control.
- You do not have any serious infections or recent live vaccines.
- You have not used certain immune-suppressing drugs like rituximab in the last year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
This trial follows patients with antiphospholipid syndrome over time to learn more about the condition. It may help researchers understand how the disease progresses and how to better manage it.
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
This study tests whether sirolimus (an immune-calming drug) is safe and helpful for people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. If you join, you'll get either sirolimus or a placebo alongside your usual treatment, to see if it reduces clotting problems.
This study looks at how well belimumab works in people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. It aims to see if the treatment helps, regardless of how well it worked in the past.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.